Cargando…
Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer
BACKGROUND: [(18)F]fluorothymidine (FLT) has been proposed as a positron emission tomography (PET)-imaging biomarker of proliferation for breast cancer. The aim of this prospective study was to assess the feasibility of FLT-PET-CT as a technique for predicting the response to neoadjuvant chemotherap...
Autores principales: | Woolf, D K, Beresford, M, Li, S P, Dowsett, M, Sanghera, B, Wong, W L, Sonoda, L, Detre, S, Amin, V, Ah-See, M-L, Miles, D, Makris, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056049/ https://www.ncbi.nlm.nih.gov/pubmed/24832174 http://dx.doi.org/10.1038/bjc.2014.207 |
Ejemplares similares
-
FLT PET-CT in evaluation of treatment response
por: Sanghera, Bal, et al.
Publicado: (2014) -
Investigation of Dose Minimisation Protocol for (18)F-FDG PET-CT in the Management of Lymphoma Postchemotherapy Followup
por: Sonoda, L. I., et al.
Publicado: (2012) -
Limits of [(18)F]-FLT PET as a Biomarker of Proliferation in Oncology
por: McKinley, Eliot T., et al.
Publicado: (2013) -
Cell proliferation detected using [(18)F]FLT PET/CT as an early marker of abdominal aortic aneurysm
por: Gandhi, Richa, et al.
Publicado: (2019) -
(18)F-FLT PET/CT in Patients with Gastric Carcinoma
por: Małkowski, Bogdan, et al.
Publicado: (2013)